Development and Validation of a High Performance Thin Layer Chromatographic Method for Quantitative Analysis of Saxagliptin

Salvala Srividya; Ettireddy Swetha; Ciddi Veeresham

doi:10.4236/ajac.2015.610076

Home > Journals > Chemistry & Materials Science > AJAC

American Journal of Analytical Chemistry > Vol.6 No.10, September 2015

Development and Validation of a High Performance Thin Layer Chromatographic Method for Quantitative Analysis of Saxagliptin ()

Salvala Srividya, Ettireddy Swetha, Ciddi Veeresham^*

University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India.

DOI: 10.4236/ajac.2015.610076 PDF HTML XML 2,218 Downloads 2,794 Views Citations

Abstract

A simple, specific, accurate and precise high performance thin layer chromatographic method (HPTLC) was developed for the quantitative analysis of Saxagliptin in active pharmaceutical ingredients (APIs) and pharmaceutical dosage forms. The method was achieved using silica gel aluminum plate 60 F₂₅₄ (10 × 10 cm) as stationary phase and Methanol:Chloroform (6:4 v/v) as mobile phase. The developed plate was scanned densitometrically using UV 222 nm wavelength. The R_f value of Saxagliptin was found to be 0.50 ± 0.02. The developed method was validated according to ICH guidelines. Limit of detection (LOD) and limit of quantification (LOQ) of Saxagliptin by this method were found as 7.96 ng/spot and 26.54 ng/spot, respectively. The method was found to be sensitive, specific, linear, accurate, precise and robust for the quantitative analysis of Saxagliptin in both APIs and marketed tablet formulation.

Keywords

HPTLC, Saxagliptin, Quantitative Analysis, Stress Induced Degradation, Validation, API

Share and Cite:

Srividya, S. , Swetha, E. and Veeresham, C. (2015) Development and Validation of a High Performance Thin Layer Chromatographic Method for Quantitative Analysis of Saxagliptin. American Journal of Analytical Chemistry, 6, 797-806. doi: 10.4236/ajac.2015.610076.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Li, C.J., Liu, X.J., Bai, L., Yu, Q., Zhang, Q.M., Yu, P. and Yu, D.M. (2014) Efficacy and Safety of Vildagliptin, Saxagliptin or Sitagliptin as Add-On Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Dual Combination of Traditional Oral Hypoglycemic Agents. Diabetology & Metabolic Syndrome, 6, 1-9. http://dx.doi.org/10.1186/1758-5996-6-69
[2]	Qaseem, A., Linda, L.H., Donna, E.S., Melissa, S. and Paul, S. (2012) Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine, 156, 218-231. http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00011
[3]	Saine, M.E., Carbonari, D.M., Newcomb, C.W., Melissa, S.N., Kevin, H., Vincent, L.R., et al. (2015) Determinants of Saxagliptin Use among Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-Diabetic Drugs. BMC Pharmacology and Toxicology, 16, 1-16. http://dx.doi.org/10.1186/s40360-015-0007-z
[4]	Scheen, A.J., Charpentier, G., Ostgren, C.J., Hellqvist, A. and Gause-Nilsson, I. (2010) Efficacy and Safety of Saxagliptin in Combination with Metformin Compared with Sitagliptin in Combination with Metformin in Adult Patients with Type 2 Diabetes Mellitus. Diabetes Metabolism Research and Reviews, 26, 540-549. http://dx.doi.org/10.1002/dmrr.1114
[5]	Deacon, C.F. (2011) Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes: A Comparative Review. Diabetes, Obesity and Metabolism, 13, 7-18. http://dx.doi.org/10.1111/j.1463-1326.2010.01306.x
[6]	Michael, E.C. and Robert, F. (2012) Saxagliptin for the Treatment of Type 2 Diabetes Mellitus: Assessing Cardiovascular Data. Cardiovascular Diabetology, 11, 1-8.
[7]	Sravana Kumara, K. and Sailaja, B. (2015) Analytical Method Development and Validation for Estimation of Dipeptidyl Peptidase-4 Inhibitors: A Review. International Journal of Current Research in Chemistry and Pharmaceutical Sciences, 2, 83-98.
[8]	Kalaichelvi, R. and Jayachandran, E. (2011) Validated Spectroscopic Method for estimation of Saxagliptin in Pure and from Tablet Formulation. International Journal of Pharmacy and Pharmaceutical Sciences, 3, 179-180.
[9]	Ramalingam, K. and Jayachandran, E. (2012) Extractive Spectrophotometric Estimation of Saxagliptin in Pure and in Pharmaceutical Dosage Form. American Journal of Pharma Tech Research, 2, 429-433.
[10]	Serife, E.K.T., Mustafa, V.K. and Demet, D. (2013) An HPLC Method for the Determination of Saxagliptin in Human Plasma with Fluorescence Detection. Journal of Advances in Chemistry, 3, 810-818.
[11]	Vaishali, V. and Anand Kumara, D. (2013) Development and Validation of a Liquid Chromatographic Method for Estimation of Saxagliptin in Tablet Dosage Form. Asian Journal of Research in Chemistry, 6, 552-554.
[12]	Gao, J., Yuan, Y., Lu, Y. and Yao, M. (2012) Development of A rapid UPLC-MS/MS Method for Quantification of Saxagliptin in Rat Plasma and Application to Pharmacokinetic Study. Biomed Chromatography, 26, 1482-1487. http://dx.doi.org/10.1002/bmc.2720
[13]	Xiaohui, X., Roger, D., Huidong, G., Lisa, J., Christophera, H.S., Laura, C., et al. (2012) Liquid Chromatography and Tandem Mass Spectrometry Method for the Quantitative Determination of Saxagliptin and Its Major Pharmacologically Active 5-Monohydroxy Metabolite in Human Plasma: Method Validation and Overcoming Specific and Non-Specific Binding at Low Concentrations. Journal of Chromatography B, 889-890, 77-86. http://dx.doi.org/10.1016/j.jchromb.2012.01.033